Comparative Pharmacology
Head-to-head clinical analysis: GASTROCROM versus INTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROCROM versus INTAL.
GASTROCROM vs INTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
Mast cell stabilizer; inhibits degranulation of sensitized mast cells by blocking release of histamine and other inflammatory mediators.
200 mg orally four times daily, 30 minutes before meals and at bedtime.
2 inhalations (2 mg each) via nebulizer 4 times daily; or 20 mg via inhalation powder (Spinhaler) 4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Terminal elimination half-life: 1.5-2 hours in plasma; clinical effect persists longer due to mast cell stabilization in airways.
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Primarily renal: unchanged drug (50-70%) and conjugated metabolites (20-30%); biliary/fecal: <5%.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer